A. Kohls

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Annals of Oncology · 2017 · 172 citations

Medicine, Oncology, Pharmacology +17

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

Medicine, Oncology, Pharmacology +15

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

Oleg Gluz, Ulrike Nitz, Cornelia Liedtke et al. · JNCI Journal of the National Cancer Institute · 2017 · 132 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer

Sherko Kümmel, J. Krocker, A. Kohls et al. · British Journal of Cancer · 2006 · 53 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study

Naiba Nabieva, Tanja Fehm, Lothar Häberle et al. · European Journal of Cancer · 2018 · 49 citations

Medicine, Oncology, Pharmacology +17